PVR and neoplasm: In a study of 10 fresh tumor samples from untreated TNBC patients, TIGIT overexpression was found in CD8+ and CD4+ TILs, and highly expressed TIGIT and its ligands (CD155 and CD112) were discovered in tumor cells and antigen-presenting cells (51).